192.51
Natera Inc stock is traded at $192.51, with a volume of 1.09M.
It is down -1.28% in the last 24 hours and up +17.45% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$195.00
Open:
$196.77
24h Volume:
1.09M
Relative Volume:
0.87
Market Cap:
$26.42B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-101.26
EPS:
-1.9012
Net Cash Flow:
$94.06M
1W Performance:
+5.96%
1M Performance:
+17.45%
6M Performance:
+24.62%
1Y Performance:
+61.54%
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NTRA
Natera Inc
|
192.51 | 26.76B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
572.50 | 215.96B | 43.74B | 6.59B | 6.11B | 17.30 |
|
DHR
Danaher Corp
|
223.01 | 157.33B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
640.85 | 51.09B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
148.03 | 41.80B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
220.52 | 37.38B | 15.70B | 1.24B | 2.01B | 6.9036 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Price momentum metrics for Natera Inc. explainedJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com
Why Natera Inc. stock could see breakout soonWeekly Investment Summary & Expert Approved Trade Ideas - newser.com
Ranking Natera Inc. among high performing stocks via toolsEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
How high can Natera Inc. stock goJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key resistance and support levels for Natera Inc.Weekly Trade Recap & High Return Trade Opportunity Guides - newser.com
Using portfolio simulators with Natera Inc. includedWeekly Market Outlook & Stock Portfolio Risk Control - newser.com
Automated trading signals detected on Natera Inc.Weekly Trade Recap & AI Powered Market Entry Ideas - newser.com
Is Natera Inc. stock positioned well for digital economyJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Regression analysis insights on Natera Inc. performance2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Will Natera Inc. stock outperform Nasdaq indexPrice Action & Risk Controlled Daily Trade Plans - newser.com
Published on: 2025-10-25 22:46:18 - newser.com
Natera, Inc. Stock (NTRA) Opinions on IMvigor011 Trial Success - Quiver Quantitative
Natera Inc stock hits all-time high at 196.77 USD - Investing.com India
Natera Inc stock hits all-time high at 196.77 USD By Investing.com - Investing.com Canada
Natera CFO Brophy sells $412,951 in NTRA stock By Investing.com - Investing.com UK
Natera CFO Brophy sells $412,951 in NTRA stock - Investing.com India
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):